SEOUL, South Korea, Dec. 12, 2022 /PRNewswire/ — RF Medical Co., Ltd. is a premier Korean-based medical company serving the healthcare industry for almost two decades. Recently, FDA cleared RF Medical’s patented MYGEN™ M-3004 generator and MYOBLATE™ radiofrequency ablation system.
FDA clears RF Medical’s MYGEN™ M-3004 and MYOBLATE™ Radiofrequency Ablation System.
Radiofrequency ablation is evolving at a rapid pace. Commonly used to treat damaged tissue and tumors, the technology enabling fulguration or radiofrequency ablation is in high demand among surgeons and medical practices worldwide.
RF Medical Co., Ltd. is a leading Korean thermal ablation system manufacturer and the creator of the critically acclaimed MYGEN™ M-3004 generator and specialized electrodes including MYOBLATE™. Both of these products have been cleared by FDA and are now commercially available in the United States.
RF Medical’s chief executive officer Mike Jun imparted that the company is delighted to extend some of its finest medical equipment to the American market. Mr. Jun is confident that MYGEN™ and MYOBLATE™ will empower US-based medical facilities and practices, and will modernize the standard of care for minimally-invasive practices in the United States.
According to Mr. Mike Jun, RF Medical’s commitment to developing effective, affordable, and minimally invasive medical devices is embodied in its latest inventions, communicating the following:
"The world’s medical device market is showing remarkable growth driven by cutting-edge minimally invasive technology and its industrial value is limitless. RF Medical is working diligently in an effort to keep pace with the advanced medical market. Improving the health and safety of mankind is our top priority and we are dedicated to carrying our mission as a leading medical device company through continuous investments in superior workforce and R&D," said Mike Jun, the CEO of RF Medical.
The MYGEN™ M-3004 is a medical device that enables a combination of monopolar and bipolar modes. In addition to delivering radiofrequency energy more effectively, it also supports optimized algorithm modes for use in a variety of lesions depending on their size and shape.
MYOBLATE™ electrodes are intended for use in percutaneous and intraoperative coagulation and ablation of tissue. MYOBLATE™ utilizes RFA (radiofrequency ablation), which is a therapeutic form of heat-treatment approach, to safely treat lesions individually while preserving the minimally invasive nature of the procedure and keeping adjacent tissues intact.
More information about MYOBLATE™ and MYGEN™ is available on RF Medical’s official website.
Contact details:
Company: RF Medical Co., Ltd.
Email Address: [email protected]
Contact: Public Relations
Contact Phone: +82-2-2108-4200
Country: Korea
Website: www.rfa.co.kr, www.myoblate.com
Source : FDA clears RF Medical's MYGEN™ M-3004 and MYOBLATE™ Radiofrequency Ablation System
>
This content was prepared by our news partner, Cision PR Newswire. The opinions and the content published on this page are the author’s own and do not necessarily reflect the views of Siam News Network
